COMPOSITION :
Soraclav -625 : |
Each film coated tablet contains : |
|
 |
Amoxycillin Trihydrate IP equivalent to Amoxycillin |
…………. |
500 mg. |
Potassium clavulanate IP equivalent to Clavulanic acid |
…………. |
125 mg. |
|
Soraclav-375 : |
Each film coated tablet contains : |
|
 |
Amoxycillin Trihydrate IP equivalent to Amoxycillin |
…………. |
250 mg. |
Potassium clavulanate IP equivalent to Clavulanic acid |
…………. |
125 mg. |
|
Soraclav SYRUP : |
Each 5 ml of reconstituted suspension contains : |
|
 |
Amoxycillin Trihydrate IP equivalent to Amoxycillin |
…………. |
200 mg. |
Potassium clavulanate IP equivalent to Clavulanic acid |
…………. |
28.5 mg. |
|
Soraclav is an oral antibacterial combination consisting of the semisynthetic
antibiotic amoxicillin and the β-lactamase inhibitor clavulanic acid.
MECHANISM OF ACTION :
Soraclav is an oral antibacterial combination consisting of the semisynthetic
antibiotic amoxycillin and the β-lactamase inhibitor clavulanate potassium
(the potassium salt of clavulanic acid).
Amoxycillin : Amoxycillin is an analog of ampicillin, derived from the basic
penicillin nucleus 6-aminopenicillanic acid. It inhibits cross-linkage between
the linear peptidoglycan polymer chains that make up a major component of the
cell walls of both Gram-positive and Gram-negative bacteria. Amoxycillin inhibits
bacterial cell wall synthesis by binding to one or more of the penicillin-binding
proteins (PBPs) which in turn inhibits the final transpeptidation step of
peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall
biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall
autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Clavulanic acid is a β-lactam structurally related to the penicillins and possesses
the ability to inactivate a wide variety of β-lactamases by blocking the active sites
of these enzymes. Clavulanic acid is particularly active against the clinically important
plasmid-mediated β-lactamases frequently responsible for transferring drug resistance to
penicillins and cephalosporins.
Rationale for combination : Amoxycillin is susceptible to degradation by β-lactamases.
The clavulanic acid component of NEOCLAV protects amoxicillin from degradation by β-lactamase
enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria
normally resistant to amoxicillin and other β-lactam antibiotics.
INDICATIONS :
Soraclav formulations are indicated for the treatment of infections caused by
amoxycillin resistant organisms producing beta-lactamases sensitive to clavulanic acid:
Upper respiratory tract infections, such as sinusitis, recurrent otitis media,
tonsillitis.Lower respiratory tract infections, such as bronchitis (caused by
amoxycillin resistant beta-lactamase producing Escherichia coli, Haemophilus
influenzae andHaemophilus para-influenzae), bronchopneumonia.
Genito-urinary tract infections, such as cystitis, urethritis,
pyelonephritis. Skin and soft tissue infections.
Soraclav formulations will also be effective in the treatment of infections
caused by amoxycillin sensitive organisms at the appropriate amoxycillin dosage
since in this situation the clavulanic acid component does not contribute to the therapeutic effect.
DOSAGE AND DIRECTIONS FOR USE :
Tablets should be taken immediately before a meal.
Dosages:
General Information:
For infections caused by amoxycillin-sensitive organisms the dosage is that approved
for amoxycillin as the clavulanic acid component does not contribute to the therapeutic effect.
Adult:
The adult dose for Soraclavis one or two Soraclav 375 tablet(s) every eight
hours at the start of a meal. For more severe infections and infection of
the respiratory tract, the dose should be one Soraclav 625 tablet every eight
hours at the start of a meal.
Since Soraclav 375 and 625 tablets contain the same amount of clavulanic
acid (125 mg, as the potassium salt), two Soraclav 375 tablets are not equivalent
to one Soraclav 625 tablet. Therefore, two Soraclav 375 tablets should not be
substituted for one Soraclav 625 tablet for the treatment of more severe infections.
DOSAGE GUIDE:
AMOXYCILLIN SENSITIVE ORGANISMS
PRODUCT |
UPPER RESPIRATORY TRACT INFECTIONS |
LOWER RESPIRATORY TRACT INFECTIONS |
URINARY TRACT INFECTIONS |
SKIN AND SOFT TISSUE INFECTIONS |
ADULTS: |
|
|
|
|
Soraclav 375 |
1 - 2 tablets 8 hourly |
1 - 2 tablets 8 hourly |
1 - 2 tablets 8 hourly |
1 - 2 tablets 8 hourly |
Soraclav 625 |
1 tablet 8 hourly |
1 tablet 8 hourly |
1 tablet 8 hourly |
1 tablet 8 hourly |
|
AMOXYCILLIN RESISTANT ORGANISMS
PRODUCT |
UPPER RESPIRATORY TRACT INFECTIONS
(otitis media) H. influenzae H. para influenzae |
LOWER RESPIRATORY TRACT INFECTIONS
(bronchitis) H. influenzae H. para influenzae |
URINARY TRACT INFECTIONS
E. coli Klebsiella pneumoniae |
SKIN AND SOFT TISSUE INFECTIONS
Staphylococcus aureus |
ADULTS: |
|
|
|
|
Soraclav 375 |
2 tablets 8 hourly |
2 tablets 8 hourly |
2 tablets 8 hourly |
2 tablets 8 hourly |
Soraclav 625 |
1 tablet 8 hourly |
1 tablet 8 hourly |
1 tablet 8 hourly |
1 tablet 8 hourly |
|
CONTRA-INDICATIONS :
In patients with a history of hypersensitivity to beta-lactams, e.g. penicillins
and cephalosporins. Safety in pregnancy has not been established. There
is limited information on the use of Soraclav in human pregnancy.
Use should be avoided in pregnancy unless considered essential by the physician. Soraclav is contra-indicated in patients with a previous history ofSoraclav -associated jaundice/hepatic dysfunction.
ADVERSE EFFECTS :
The majority of side effects observed were of a mild and transient nature.
The most frequently reported adverse effects which were suspected or
probably drug-related were diarrhea (14.5%), vaginal mycosis (3.3%) nausea
(2.1%), and loose stools (1.6%).
Other adverse effects that are common for the ampicillin group of antibiotics
and may occur during use of amoxicillin are: GI effects like diarrhea, nausea,
vomiting, indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue,
mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudo-membranous
colitis; Hypersensitivity reactions like skin rashes, pruritus, urticaria,
angioedema, serum sickness-like reactions; A moderate rise in AST (SGOT)
and/or ALT (SGPT), interstitial nephritis and hematuria; CNS effects like agitation,
anxiety, behavioral changes, confusion, convulsions, dizziness, headache, insomnia.
WARNINGS / PRECAUTIONS :
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have
been reported in patients on penicillin therapy. Careful inquiry should be made
concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.
Prolonged use may result in fungal or bacterial super infection, including C.
difficile-associated diarrhea (CDAD) and pseudo-membranous colitis; CDAD has been
observed >2 months post antibiotic treatment.
While amoxicillin/clavulanate potassium combination possesses the characteristic
low toxicity of the penicillin group of antibiotics, periodic assessment of organ
system functions, including renal, hepatic, and hematopoietic function, is advisable
if therapy is for longer than the drug is approved for administration.
DRUG INTERACTIONS :
Allopurinol: The concurrent administration of allopurinol may increase
the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone.
BCG Vaccine: Antibiotics may diminish the therapeutic effect of BCG.
Fusidic Acid: May diminish the therapeutic effect of Penicillins.
Methotrexate: Penicillins may decrease the excretion of Methotrexate.
Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s)
of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.
Oral Contraceptives: In common with other broad-spectrum antibiotics, amoxicillin may
reduce the efficacy of oral contraceptives.
Probenecid: decreases the renal tubular secretion of amoxicillin. Concurrent use with
amoxicillin may result in increased and prolonged blood levels of amoxicillin. Co-administration
of probenecid cannot be recommended.
Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only
the live attenuated Ty21a strain is affected.
PACKAGING INFORMATION :
Soraclav -625: Available in a strip of 6 tablets.
Soraclav-375: Available in a strip of 6 tablets.
SoraclavSYRUP: Available in 30 ml bottle pack.